Seqens Paracetamol Plant Faces Geopolitical, Price Pressures

Seqens, a French pharmaceutical manufacturer, warns that its new paracetamol plant is under pressure from Middle East tensions, foreign competition, and renegotiated lower purchase prices. The project, costing over €100 million, aims to produce a 100% French active ingredient but faces an uncertain market outlook.